Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database.
Best
Jennie H
JH
Amylin Pharmaceuticals, San Diego, California, USA. jennie.best@amylin.com
Hoogwerf
Byron J
BJ
Herman
William H
WH
Pelletier
Elise M
EM
Smith
Daniel B
DB
Wenten
Made
M
Hussein
Mohamed A
MA